- Home
- GCMG vs SEPN Comparison
GCMG vs SEPN Comparison
Compare GCMG & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- SEPN
- Stock Information
- Founded
- GCMG 1971
- SEPN 2022
- Country
- GCMG United States
- SEPN United States
- Employees
- GCMG N/A
- SEPN 75
- Industry
- GCMG Finance/Investors Services
- SEPN
- Sector
- GCMG Finance
- SEPN
- Exchange
- GCMG Nasdaq
- SEPN NYSE
- Market Cap
- GCMG 631.4M
- SEPN 553.0M
- IPO Year
- GCMG N/A
- SEPN 2024
- Fundamental
- Price
- GCMG $11.67
- SEPN $12.21
- Analyst Decision
- GCMG Hold
- SEPN Strong Buy
- Analyst Count
- GCMG 5
- SEPN 5
- Target Price
- GCMG $14.00
- SEPN $26.75
- AVG Volume (30 Days)
- GCMG 419.2K
- SEPN 222.3K
- Earning Date
- GCMG 08-07-2025
- SEPN 08-15-2025
- Dividend Yield
- GCMG 3.73%
- SEPN N/A
- EPS Growth
- GCMG N/A
- SEPN N/A
- EPS
- GCMG 0.14
- SEPN N/A
- Revenue
- GCMG $530,455,000.00
- SEPN $977,000.00
- Revenue This Year
- GCMG $2.72
- SEPN $3,429.67
- Revenue Next Year
- GCMG $12.99
- SEPN N/A
- P/E Ratio
- GCMG $86.73
- SEPN N/A
- Revenue Growth
- GCMG 17.38
- SEPN 108.76
- 52 Week Low
- GCMG $10.04
- SEPN $4.17
- 52 Week High
- GCMG $14.48
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- GCMG 42.37
- SEPN N/A
- Support Level
- GCMG $11.70
- SEPN N/A
- Resistance Level
- GCMG $12.08
- SEPN N/A
- Average True Range (ATR)
- GCMG 0.23
- SEPN 0.00
- MACD
- GCMG -0.01
- SEPN 0.00
- Stochastic Oscillator
- GCMG 15.07
- SEPN 0.00
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.